All In Biotech

Drug Trial Radar · NCT07275645

A Clinical Trial of Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried in a Population Aged 10 to 60 Years

A Phase III, Randomized, Blinded, and Homologous Vaccine-Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of the Rabies Vaccine (Human Diploid Cell), Freeze-dried, Vaccinated With Different Immunization Schedules in a Population Aged 10 to 60 Years

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Feb 26, 2026

Primary completion

Nov 26, 2026

Study completion Apr 26, 2027

Sponsor

Lead sponsor
Ab&B Bio-tech Co., Ltd.JSAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 10 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A total of 3,000 participants will be enrolled, stratified by age into two groups: 600 participants aged 10-17 years and 2,400 participants aged 18-60 years. Within each age group, participants will be randomly assigned in a 1:1:1:1:1 ratio to one of five vaccination schedule groups: Essen Control Group (Group A), Essen Experimental Group (Group B), Zagreb Experimental Group (Group C), Simplified Four-Dose Group 1 (Group D), and Simplified Four-Dose Group 2 (Group E). Among participants in the four experimental groups-Essen Experimental Group, Zagreb Experimental Group, Simplified Four-Dose Group 1, and Simplified Four-Dose Group 2-stratified block randomization will be applied. Within each age group and each vaccination schedule group, participants will be further randomized in a 1:1:1 ratio into three subgroups: those receiving a booster dose at Day 90 after completion of the primary immunization, those receiving a booster dose at Day 180, and those undergoing assessment of immune persistence at Day 360 after completion of the primary immunization.

Conditions

  • Rabies

Interventions

  • Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-driedBiological

    The vaccine will be administered via intramuscular injection into the deltoid muscle of the upper arm, with a human dose of 1.0 ml per injection. A total of 5 doses will be administered at Day 0, 3, 7, 14, and 28. Some participants will also undergo re-exposure immunization, receiving one additional dose of the vaccine on Days 0 and 3 of the re-exposure phase.

  • Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-driedBiological

    The vaccine will be administered via intramuscular injection into the deltoid muscle of the upper arm, with a human dose of 1.0 ml per injection. Two doses will be administered on Day 0, followed by one dose each on Days 7 and 21, for a total of 4 doses. Some participants will also undergo re-exposure immunization, receiving one additional dose of the vaccine on Days 0 and 3 of the re-exposure phase.

  • Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-driedBiological

    The vaccine will be administered via intramuscular injection into the deltoid muscle of the upper arm, with a human dose of 1.0 ml per injection. A total of 4 doses will be administered at Day 0, 3, 7 and 14. Some participants will also undergo re-exposure immunization, receiving one additional dose of the vaccine on Days 0 and 3 of the re-exposure phase.

  • Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-driedBiological

    The vaccine will be administered via intramuscular injection into the deltoid muscle of the upper arm, with a human dose of 1.0 ml per injection. A total of 4 doses will be administered at Day 0, 3, 7, and 28. Some participants will also undergo re-exposure immunization, receiving one additional dose of the vaccine on Days 0 and 3 of the re-exposure phase.

  • Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-driedBiological

    The vaccine will be administered via intramuscular injection into the deltoid muscle of the upper arm, with a human dose of 1.0 ml per injection. A total of 5 doses will be administered at Day 0, 3, 7, 14, and 28.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies in baseline seronegative participants 14 days after the first dose.Time frame: Day 14 after the first dose.
  2. Seroconversion rate of rabies virus neutralizing antibodies in baseline seronegative participants 14 days after the last dose.Time frame: Day 14 after the last dose.
  3. Incidence of adverse events within different timeframes (30 minutes, 0-7 days, 0-30 days) after each vaccine dose.Time frame: Within 30 minutes, 0-7 days, and 0-30 days after each dose
  4. All serious adverse events (SAEs) occurring from the first dose of primary immunization to 6 months after completion of the primary immunization.Time frame: From the first dose of primary immunization to 6 months after completion

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Qichun County Center for Disease Control and Prevention

    Huanggang, Hubei, China

  • Yunyang District Center for Disease Control and Prevention

    Shiyan, Hubei, China

  • Zhushan county Center for Disease control and Prevention

    Shiyan, Hubei, China

  • Gucheng county Center for Disease control and Prevention

    Xiangyang, Hubei, China

  • Xiangzhou District Center for Disease Control and Prevention

    Xiangyang, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.